BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zedira Release: Structure of Active Coagulation Factor XIII Published – Milestone on the Way to Safe Anticoagulation October 14th, Darmstadt, Germany


10/14/2013 8:07:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

October 14th, Darmstadt, Germany -- Zedira, in cooperation with the group of Prof. Gerhard Klebe in Marburg, reported the first crystal structure of coagulation factor XIII in the active conformation. The article is now published in Angewandte Chemie International Edition and provides a proprietary high-resolution structure of FXIIIa in complex with the inhibitor ZED1301 serving as lead structure. The data are of enormous value for structure based drug design. Direct acting Factor XIIIa-blockers may provide a novel and safe option for preventing thrombotic events. Such inhibitors would not impair the thrombin level or primary clot formation by platelet activation, but would effectively reduce the mechanical stability and half-life of clots, thereby accelerating fibrinolysis. This approach has the potential of overcoming the apparent strong link between anticoagulation and life threatening bleeding tendencies that limit the use of anticoagulants today.

In conclusion, Zedira has further strengthened its leading technological position with this cutting edge scientific publication. The company emphasizes its claim of being a preferred partner for the established pharmaceutical industry.

About Zedira:

The Darmstadt-based biopharmaceutical company focuses on the transglutaminase family of enzymes. Based on its patented family of low-molecular weight transglutaminase blockers, Zedira is establishing an active ingredient pipeline. Drug candidate ZED1227 for the indication celiac disease has been successfully out licensed in 2011. As an area of secondary indication Zedira is working on new approaches to thrombosis prophylaxis. The company develops, produces and markets products for research and development as well as for diagnostics.

The research was supported by a grant of the German Federal Ministry of Education and Research (BMBF, FKZ 0316030).

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES